“The Applicant evaluated the safety of zidesamtinib administered orally twice daily in GLP-compliant 28-day and 13-week repeat-dose general toxicology studies in Wistar-Han rats and Beagle dogs.”
✓ VerifiedFDA multi-discipline review, p. 37Source ↗
Why that species
Metabolite profiles similar to human (including M9) and ability to achieve adequate systemic exposure
“The Wistar-Han rat and beagle dog were selected as appropriate species for toxicity based on having metabolite profiles similar to human (inclusive of the main des-ethyl metabolite in patients designated M9) and ability to achieve adequate systemic exposure.”
✓ VerifiedFDA multi-discipline review, p. 49Source ↗
Surrogate molecule
No surrogate; the clinical compound was tested
“The Applicant evaluated the safety of zidesamtinib administered orally twice daily in GLP-compliant 28-day and 13-week repeat-dose general toxicology studies in Wistar-Han rats and Beagle dogs.”
✓ VerifiedFDA multi-discipline review, p. 37Source ↗